SCHEMBL2668952

SCHEMBL2668952

Cc1nc2ncccn2n1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 2/20 0.47
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46
ALDH1A1 P00352 5/20 0.41
TSHR P16473 1/20 0.41
PIK3CG P48736 1/20 0.41
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
KDM4E B2RXH2 4/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
HPGD P15428 4/20 0.36
MAPT P10636 1/20 0.36
HSD17B10 Q99714 2/20 0.35
SMPD3 Q9NY59 2/20 0.35
THRB P10828 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7195074 0.77 PDE10A (0.45) PDE10ARAB9ANPC1ALDH1A1TSHR
SCHEMBL21389568 0.77 PDE10A (0.45) PDE10ARAB9ANPC1ALDH1A1TSHR
SCHEMBL12989975 0.77 PDE10A (0.45) PDE10ARAB9ANPC1ALDH1A1TSHR
SCHEMBL10921639 0.77 PDE10A (0.45) PDE10ARAB9ANPC1ALDH1A1TSHR
SCHEMBL259293 0.77 PDE10A (0.45) PDE10ARAB9ANPC1ALDH1A1TSHR
SCHEMBL858832 0.77 MAP4K4 (0.46) PDE10ARAB9ANPC1ALDH1A1TSHR
SCHEMBL9933090 0.77 PDE10A (0.45) PDE10ARAB9ANPC1ALDH1A1TSHR
SCHEMBL12091358 0.76 NPC1 (0.42) PDE10ARAB9ANPC1ALDH1A1TSHR
SCHEMBL13954223 0.76 NPC1 (0.45) PDE10ARAB9ANPC1ALDH1A1TSHR
SCHEMBL7066910 0.76 NPC1 (0.56) PDE10ARAB9ANPC1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025233865-A1 ENPP1 INHIBITORS RE VENTURES I, LLC (US) 2025-11-13 WO disclosed
EP-3675847-B1 SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME H LUNDBECK AS (DK) 2023-07-12 EP disclosed
US-20230150983-A1 LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2023-05-18 US disclosed
US-11446398-B2 Regulated biocircuit systems OBSIDIAN THERAPEUTICS, INC. (US) 2022-09-20 US disclosed
US-20210347773-A1 ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS ONO PHARMACEUTICAL CO., LTD. (JP) 2021-11-11 US disclosed
EP-3885340-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2021-09-29 EP disclosed
EP-3397640-B1 XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS INST NAT SANTE RECH MED (FR) 2021-08-04 EP disclosed
US-11046683-B2 Activator of TREK (TWIK RElated K+ channels) channels ONO PHARMACEUTICAL CO., LTD. (JP) 2021-06-29 US disclosed
US-20210186958-A1 GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-06-24 US disclosed
EP-3369732-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2021-05-26 EP disclosed
US-20070135477-A1 Benzimidazole derivatives and their use as protein kinases inhibitors ASTEX THERAPEUCTICS, LIMITED (US) 2007-06-14 US disclosed
US-20060201819-A1 electrochemical graining treatment in hydrochloric acid solution and an alkali etching treatment; aluminum electrodeposition; excellent in press life and scum resistance; recording layer is formed on the grained surface of the support is excellent in all of sensitivity, press life, mechanical strength FUJI PHOTO FILM CO., LTD. 2006-09-14 US disclosed
WO-2006070192-A1 THIAZOLE AND ISOTHIAZOLE DERIVATIVES THAT MODULATE THE ACIVITY OF CDK, GSK AND AURORA KYNASES ASTEX THERAPEUTICS LIMITED (GB) 2006-07-06 WO disclosed
WO-2005002552-A2 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2005-01-13 WO disclosed
US-5066572-A CONTROL OF PRESSURE-FOG WITH GELATIN-GRAFTED AND CASE-HARDENED GELATIN-GRAFTED SOFT POLYMER LATEX PARTICLES EASTMAN KODAK COMPANY (US) 1991-11-19 US disclosed
EP-0430003-A1 Light-sensitive silver halide color photographic material KONICA CORPORATION (JP) 1991-06-05 EP disclosed
US-4826834-A BACTERICIDES TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1989-05-02 US disclosed
EP-0295583-A2 Silver halide color photographic material FUJI PHOTO FILM CO., LTD. (JP) 1988-12-21 EP disclosed
EP-0216385-A2 Antibacterial compounds Takeda Chemical Industries, Ltd. (JP) 1987-04-01 EP disclosed
US-4131467-A 4,7-Dihydroxybenzimidazole hydrobromide as antifogger E. I. DU PONT DE NEMOURS AND COMPANY (US) 1978-12-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210186958-A1 GLYCOSIDASE INHIBITORS ENGASE, GAA, GLA PDE10A 2857/4885RAB9A 931/4885NPC1 449/4885
US-20230150983-A1 LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME LAGE3, CRY1, CRY2 PDE10A 3148/4885RAB9A 1502/4885NPC1 3876/4885
US-11046683-B2 Activator of TREK (TWIK RElated K+ channels) channels KCNJ11, KCNJ1, KCNJ8 PDE10A 807/4885RAB9A 1432/4885NPC1 380/4885
US-20070135477-A1 Benzimidazole derivatives and their use as protein kinases inhibitors CDK1, AURKA, CDK2 PDE10A 2364/4885RAB9A 4363/4885NPC1 2920/4885
US-20210347773-A1 ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS KCNJ11, KCNJ1, KCNJ8 PDE10A 807/4885RAB9A 1432/4885NPC1 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.